The global proglumide market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Proglumide is a drug that inhibits gastrointestinal motility (GC) and reduces gastric secretions. The drug acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. The rise in the burden of peptic ulcers is one of the major factors driving the growth of the global proglumide market. Peptic Ulcers Disease (PUD) is characterized by discontinuation in the inner lining of the gastrointestinal (GI) tract due to gastric acid secretion. It usually occurs in the stomach and proximal duodenum. According to the data published by National Center for Biotechnology Information (NCBI) in 2019, peptic ulcers disease (PUD) is a global problem with a lifetime risk of development ranging from 5.0% to 10.0%, where duodenal ulcers are four times more common than gastric ulcers. Moreover, the signs and symptoms of PUD may differ depending upon the location of the disease and age. Thus, the rise in the prevalence of peptic ulcers is anticipated to drive the demand for the proglumide market during the forecast period.
Looking towards the demand for proglumide, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2019, the National Institute of Health has labeled a phase 1/2 clinical trials, designed to evaluate the safety and efficacy of an oral cholecystokinin (CCK) receptor antagonist, in subjects with NASH. Further, an extended use protocol has been approved for the risk of liver disease progression to continue proglumide at 1200mg /day for an additional 3-9 months. The dose levels of proglumide are expected to be 400mg (BID), 400mg (TID), and 800mg (BID), and 6 patients will be enrolled in each cohort starting with the lowest dose of 400mg PO BID for 12 weeks. The safety and toxicity of the patients will be monitored using Common Terminology Criteria for Adverse Events v 5 and the efficacy of the treatment will be evaluated by assessment of liver enzymes and fibroscan. Thus, such clinical trials are anticipated to drive the growth of the global proglumide market during the forecast period (2022-2028).
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Proglumide Market at https://orionmarketreports.com/request-sample/?id=94331&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Nanjing Pharmaceutical Factory Co., Ltd., Tainyuan Pharmaceutical Co.,Ltd., and Hubei Yikangyuan Chemical Co.Ltd among others
A full report is available at: https://orionmarketreports.com/global-proglumide-market/94331/
Global Proglumide Market Report by Segment
By Type
- Tablets
- Capsules
By Application
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
